Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: A population-based evaluation

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 461-464

  Vu, T ^a   Ellard, S ^a   Speers, C H ^a   Taylor, S C M ^a   de Lemos, M L ^a   Hu, F ^a   Kuik, K ^a   Olivotto, I A ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast neoplasms; Docetaxel; Paclitaxel; Taxoids; Treatment outcome

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TWO TAILED TEST;

EID: 40049112950     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm527     Document Type: Article

References (17)

1. A. Jemal R. Siegel E. Ward Cancer statistics. 2006 CA Cancer J Clin 19 3 2006 461 464
2. Canadian Cancer Society/National Cancer Institute of Canada Canadian Cancer Statistics 2006 2006 Canadian Cancer Society/National Cancer Institute of Canada Toronto, Canada
3. World Health, Organization. WHO Mortality Database http://www3.who.int/whosis/mort/table1_process.cfm (2 March 2005, date last accessed)
4. I. Jatoi A. Tsimelzon H. Weiss Hazard rates of recurrence following diagnosis of primary breast cancer Breast Cancer Res Treat 89 2 2005 173 178
5. J. O'Shaughnessy Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 Suppl 3 2005 20 29
6. NCCN Breast Cancer Panel. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2006)©2006 National Comprehensive Cancer Network, Inc. http://www.nccn.org (12 December 2006, date last accessed)
7. S.E. Jones J. Erban B. Overmoyer Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 24 2005 5542 5551
8. S.C.M. Taylor Development of a pharmacoeconomics service in a provincial oncology program Eur J Cancer 33 9 Suppl 1997 S31 (Abstr PP45)
9. S.C.M. Taylor K.T. Uyeno S.E. O'Reilly Development of a systemic therapy costing model in a provincial oncology centre Eur J Cancer 36 Suppl 3 2000 S26 (Abstr PP64)
10. D. Naimark G. Naglie A.S. Detsky The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 9 12 1994 702 707
11. P. Tappenden J. Chilcott S. Ward Methodological issues in the economic analysis of cancer treatments Eur J Cancer 42 17 2006 2867 2875
12. S. Chia C. Speers A. Kang The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population-based cohort Proc Am Soc Clin Oncol 22 2003 6 (Abstr 22)
13. D.R. Carlow The British Columbia Cancer Agency: a comprehensive and integrated system of cancer control Hosp Q 3 3 2000 31 45
14. A.D. Seidman D. Berry C. Cirrincione CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC [Meeting Abstracts] J Clin Oncol 22 Suppl 14 2004 512
15. K.S. Albain S. Nag G. Calderillo-Ruiz Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival [Meeting Abstracts] J Clin Oncol 22 Suppl 14 2004 510
16. H.J. Burstein J. Manola J. Younger Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 6 2000 1212 1219
17. E.A. Perez C.L. Vogel D.H. Irwin Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 22 2001 4216 4223